Stock Analysts

PNM Resources Introduces New Technology for Better Services

PNM Resources PNM announced that its New Mexico utility subsidiary has implemented an innovative leading-edge technology on its high-voltage transmission lines. A new type of protective relay, developed by Schweitzer Engineering Laboratories (SEL), provides significant enhancements to the reliability and functionality of the PNM grid. The ultimate objective of introducing the new technology in its transmission lines is to strengthen infrastructure and provide better services to customers at a lower cost […]

Stock Analysts

Here’s Why ITT Stock is a Fruitful Pick for Your Portfolio

Conglomerate companies are currently plagued with several supply-side challenges, including material-price inflation and soaring freight charges. Nevertheless, we believe investors should not completely shy away from these stocks in favor of retaining the core-business focused companies. Of late, domestic business prospects of these multi-sector companies have been largely buoyed by the expansionary fiscal measures rolled out by the Trump administration. […]

Stock Analysts

Is Cabot (CBT) a Suitable Stock for Value Investors Now?

Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value? One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process […]

Stock Analysts

Forget J&J, Buy These 3 Big Drug Stocks Instead in 2019

Johnson & Johnson’s JNJ stock has declined more than 14% since Reuters reported that the pharma giant knew for decades that its baby powders contained asbestos. J&J faces thousands of lawsuits related to its baby powders in the United States. These allege that its talc-based products, including its baby powders, contain asbestos, which causes its users to develop ovarian cancer. […]

Stock Analysts

AMAG Up Nearly 10% in a Year on Label Expansion, Acquisitions

Share price of AMAG Pharmaceuticals, Inc. AMAG has increased 9.7% year to date, against the industry ’s decline of 30.3%. AMAG has three marketed products — Feraheme (ferumoxytol), approved for intravenous (IV) iron replacement therapy for the treatment of iron-deficiency anemia (IDA) in adults with chronic kidney disease (CKD); Makena (hydroxyprogesterone caproate injection), a progestin approved to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth; and MuGard for the management of oral mucositis and stomatitis. […]